nounIntermediate
Definition
Synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog with modifications for extended half-life; studied for stimulating pulsatile growth hormone release.

Detailed Explanation

CJC-1295 is a modified version of the first 29 amino acids of GHRH (somatoliberin) with four amino acid substitutions that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV). A variant conjugated to drug affinity complex (DAC) — CJC-1295/DAC — binds albumin to achieve a half-life of 6–8 days. The non-DAC form (also called modified GRF 1-29) has a shorter half-life and is often combined with ipamorelin in peptide therapy protocols. Clinical data on CJC-1295 is limited; it is not FDA-approved.

Key Facts

  • CJC-1295 is a modified version of the first 29 amino acids of GHRH (somatoliberin) with four amino acid substitutions that confer resistance to enzymatic degradation by dipeptidyl peptidase IV (DPP-IV)
  • A variant conjugated to drug affinity complex (DAC) — CJC-1295/DAC — binds albumin to achieve a half-life of 6–8 days
  • The non-DAC form (also called modified GRF 1-29) has a shorter half-life and is often combined with ipamorelin in peptide therapy protocols
  • Clinical data on CJC-1295 is limited; it is not FDA-approved
Related Terms Ipamorelin Ghrelin Hormone Half-Life Acylation

Part of the PeptideBond.com education network